Sunnybrook Health Sciences Centre

Sunnybrook scientists made history by non-invasively opening the blood-brain barrier to deliver immunotherapy directly to the brain of an ALS patient using focused ultrasound technology.

A novel radiopharmaceutical developed by Stephanie Borlase will be used in a clinical trial to track immunotherapy delivery to brain metastases in lung cancer patients.

The HeLiX randomized clinical trial investigates tranexamic acid's efficacy in reducing blood loss during liver resection, a procedure often associated with significant bleeding.

Health Canada has approved vorasidenib (Voranigo) as the first targeted therapy for Grade 2 IDH-mutant glioma in adults and pediatric patients aged 12 and older, post-surgery.

A prospective trial evaluated ultrahypofractionated radiotherapy (SBRT) post-prostatectomy for localized prostate cancer, showing it is well-tolerated by patients.

Sunnybrook researchers have demonstrated the safety of using focused ultrasound to temporarily open the blood-brain barrier in ALS patients, marking a world-first clinical achievement published in Nature Communications.